2024
52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Sicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.Peer-Reviewed Original Research
2009
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
Strober B, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, Siu K, Lustgarten J, Ross E, Shapiro J. Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study. JAMA Dermatology 2009, 145: 1262-1266. PMID: 19917955, DOI: 10.1001/archdermatol.2009.264.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultAgedAlefaceptAlopecia AreataDermatologic AgentsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansInjections, IntramuscularMaleMiddle AgedNew York CityProbabilityRecombinant Fusion ProteinsRisk AssessmentSeverity of Illness IndexStatistics, NonparametricTreatment OutcomeYoung AdultConceptsSevere alopecia areataAlopecia areataPlacebo-controlled clinical trialEfficacy of alefaceptPlacebo-receiving groupSevere plaque psoriasisMain outcome measuresPlaque psoriasisPrevious therapyAlopecia ToolClinical trialsAlefaceptOutcome measuresUS FoodDrug AdministrationConsecutive weeksBiologic inhibitorsScalp hairAreataTreatmentWeeksSignificant improvementMulticenterPlaceboPsoriasis
2005
Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
Strober B, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal Of The American Academy Of Dermatology 2005, 52: 1082-1084. PMID: 15928633, DOI: 10.1016/j.jaad.2005.03.039.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisOpen-label pilot studyEfficacy of etanerceptOpen-label studyTNF-alpha inhibitorsPrimary outcome measureEnd of treatmentAlopecia ToolHair regrowthOutcome measuresEtanerceptHealthy adultsAreataContinuous treatmentPilot studySignificant regrowthTotalisTreatmentUniversalisSubjectsSeverityWeeks